Changing the standard of care in previously treated metastatic renal cell carcinoma - European Medical Journal

Continue

Changing the standard of care in previously treated metastatic renal cell carcinoma

Oncology
At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given